Innovation through HTA - VIRTUAL CONFERENCE BAG June 19-23, 2021 www.htai2021.org #HTAi2021VirtualAM
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Innovation
through HTA
VIRTUAL CONFERENCE BAG
June 19-23, 2021
www.htai2021.org
#HTAi2021VirtualAM
Dear Delegates,
Welcome to the HTAi 2021 Virtual Annual Meeting!
Each year, HTAi Annual Meetings bring together over 1,000 researchers, policymakers, industry, academia, health
service providers, agencies, patients, and consumers from around the world. The meetings provide an arena for these
groups to share information and best practices, from cutting-edge technologies to system development in order to
advance healthcare.
This year’s meeting is the first large-scale, five-day virtual event from HTAi, and we are thrilled to have you join the
excitement! From the high-caliber and engaging content, to the top-notch entertainment and abundant networking
opportunities—the 2021 Annual Meeting will be an event to remember.
The HTAi Virtual Annual Meeting will officially kick off with the Welcome Reception on Sunday, June 20 at 15:00 (UTC).
Mark your calendars now so you don’t miss out on our notable guest speaker and exceptional entertainment.
The HTAi social media team will be fully engaged throughout the entire meeting, and they want to hear from you! Use
the hashtag #HTAi2021VirtualAM to engage with fellow delegates, share your best moments, pose questions, and
provide your thoughts on the presentations you attend; we love to see your learning moments and biggest takeaways. If
you’re on LinkedIn, you can also chat with attendees in the LinkedIn virtual meeting group.
Don’t forget to tag HTAi in your posts:
Twitter: @HTAiOrg
LinkedIn: @Health Technology Assessment international (HTAi)
Facebook: @HTAiOrg
Instagram: @htai_
HTAi would like to extend a hearty thank-you to all of our volunteers, sponsors, and local hosts for working hard to
ensure this meeting is a success. If you would like to show our teams your gratitude, spend some time in our virtual
exhibition hall and interacting with our on-demand content, available in the Annual Meeting portal.
Thank you for supporting the HTAi 2021 Virtual Annual Meeting. We can’t wait to see you there!
Sincerely,
The HTAi Annual Meeting Team
HTAi 2021 Virtual Annual Meeting
TUMOR-AGNOSTIC MEDICINES FOR RARE
GENOMIC ALTERATIONS: MEETING THE
HTA AND MARKET ACCESS CHALLENGES
In the era of precision medicine, there has been a shift from organ-based to tumor-
agnostic, anti-cancer platforms, based on the molecular driver of the tumor. The recent
regulatory approval of tumor-agnostic drugs for patients with rare tropomyosin receptor
kinase (TRK) fusion cancer signals the emergence of more novel therapies targeting
specific genomic alterations.
While experts agree that randomized clinical trials are not possible for such therapies, HTA
authorities prefer them for decision making. Is there a disconnect between conventional
HTA expectations and the scientific and medical attributes of tumor-agnostic therapies?
If so, what adaptations are needed to enable evidence-based access to these therapies?
Join our panelists to gain insight into the implications of tumor-agnostic medicines for HTA
and patient access and to learn about adapted evidence requirements, characterization of
patient outcomes and valuation of these therapies.
Learning Objectives
• Understand the need to examine and redefine the pathway to market access for tumor-agnostic therapies
• Explore how clinical trial design and data collection are increasingly oriented to regulatory requirements
that have evolved and are supportive of novel mechanisms of action
• Understand how patient needs and preferences can be included among the factors considered by HTA bodies
when assessing the value of new treatments
• Compare and evaluate HTA outcomes in different countries and explore the need for flexibility and advances
in HTA processes to capture the value of tumor-agnostic therapies, including evolving evidence requirements
Monday, June 21st, 14:30 – 15:45 (UTC) VISIT HTAI.EVENTSAIR.COM/HTAI-MANCHESTER-2021-AM/SYMPOSIA
Job Code: MAC-VIT-ALL-0014-1 Date of Preparation: May 2021
HTAi 2021 Virtual Annual Meeting
TUMOR-AGNOSTIC MEDICINES FOR RARE
GENOMIC ALTERATIONS: MEETING THE
HTA AND MARKET ACCESS CHALLENGES
Agenda
Clifford Goodman
Tumor-Agnostic Medicines:
Sr. Vice President, The Lewin Group the current access situation
Carsten Bokemeyer
Transformations in cancer treatment & the
Head of Oncology, Hematology, BMT & Director Cancer Center,
challenge of collecting evidence for HTA bodies
University Medical Center Hamburg-Eppendorf
Lydia Makaroff
Incorporating patient preferences
CEO of Fight Bladder Cancer, Vice President of the World Bladder
into access decision making
Cancer Patient Coalition
Andrew Briggs
Economic modeling to mitigate HTA challenges
Professor of Health Economics, Department of Health Services when evaluating tumor-agnostic medicines –
Research & Policy, London School of Hygiene & Tropical Medicine learnings from the UK
Gérard de Pouvourville
Access and reimbursement to tumor-agnostic
Emeritus Professor, ESSEC Business School medicines – learnings from France
Bayer is at the forefront of the evolving global oncology cancers, but a patient’s individual tumor based on the genomic
landscape. It is our aspiration to transform the lives of people alterations driving its growth, rather than its location in the
impacted by cancer through science and innovation. World- body. We encourage the initiation of genomic testing early after
leading research, pharmaceutical, advocacy and academic diagnosis, so that precision medicine can be considered earlier in
partners support us with this aspiration. Together, we are paving the treatment journey. Ultimately, our goal is to make a difference
the way in innovative science with an emphasis on delivering true in the lives of patients and their families undergoing their
precision medicine treating not only organ-based cancer journey.
Monday, June 21st, 14:30 – 15:45 (UTC) VISIT HTAI.EVENTSAIR.COM/HTAI-MANCHESTER-2021-AM/SYMPOSIA
Job Code: MAC-VIT-ALL-0014-1 Date of Preparation: May 2021
Takeda
Creating better
health for people
and a brighter
future for the world
Takeda UK and Ireland
We are Takeda, Our purpose is simple: From our very beginning
a world leader in to create better in Japan in 1781, we
gastroenterology, health for people have been guided by
rare disease and and a brighter future our purpose. It inspires
specialty care for the world. In the UK everything we do and
medicine. that means putting enables us to act in
patients first. the best interests of
#1 society at
all times.
In the UK and Ireland,
“I am passionate about “At Takeda, patient-first
we are 400 people helping clinicians make a culture isn’t just a value, it’s
who bring this difference for their patients.” a way of life.”
purpose to BERNADETTE SAUNDERS, KATY, SENIOR MEDICAL SCIENCE
life through NEUROSCIENCE ACCOUNT LEAD IN
ADHD ACROSS THE LIFESPAN
LIAISON, IMMMUNOLOGY
an unwavering
commitment
to putting
the patient
first.
Driving innovation We currently Through these collaborations, we accelerate the
through partnerships have 22 active development of breakthrough scientific innovations
that can redefine the standard of patient care.
and R&D partnerships
with biotechs We have established LSHTM’s very
first fully endowed corporate chair, the
and academic Takeda Chair in Global Child Health. The
institutions in Chair supports vital research to help
reduce child deaths in low and middle-
the UK and income countries.
$1.3bn Ireland.
Our partners include:
In 2020, we agreed
R&D partnerships
in the UK worth a
potential $1.3bn.
Job code: C-ANPROM/UK/CORP/0047
www.takeda.com/en-gb Date of preparation: May 2021
OUR GLOBAL TEAM We focus on four therapeutic areas: oncology,
ARE TRANSLATING SCIENCE gastroenterology (GI), rare diseases and neuroscience.
INTO POTENTIALLY
LIFE-CHANGING MEDICINES. We also make targeted R&D investments in
plasma-derived therapies and vaccines.
Supporting patient organisations
Our “I am number 17” campaign, together with Our award-winning “In My Shoes” campaign
13 patient groups, reached 16 million people with Crohn’s & Colitis UK used an immersive app
and helped to change public perceptions of to help improve people’s understanding about
rare diseases. what it is like to live with Crohn’s or Colitis.
Working closely We work closely with the NHS to help
provide better care for patients and
new community-based nurse service to
support young people.
with the NHS increase access to potentially life-changing
healthcare services.
We have also developed a mobile app with
We are supporting the development of the local NHS services to better monitor the
Heart of England NHS Foundation Trust effectiveness of treatment.
paediatric ADHD service, establishing a
Job code: C-ANPROM/UK/CORP/0047
www.takeda.com/en-gb Date of preparation: May 2021
Health Technology Wales is a national
organisation supporting the innovation and
adoption of non-medicine technologies that will
improve health and care in Wales.
We focus on any health and care technologies that aren’t
medicines, such as:
MEDICAL DEVICES PSYCHOLOGICAL THERAPIES REHABILITATION
SURGICAL PROCEDURES TELEMONITORING CARE PATHWAYS
We work with people across the health and care landscape:
NHS WALES HEALTH & SOCIAL CARE PROFESSIONALS PUBLIC
ACADEMICS WELSH GOVERNMENT
PATIENTS TECHNOLOGY DEVELOPERS CARERS
Our work focuses on three main areas:
IDENTIFICATION Responding to the needs of service users,
healthcare providers and technology developers
across Wales.
‘Horizon scanning’ to identify upcoming
technologies that may have a major impact on
Wales in the future.
Signposting technology developers to
organisations that can give advice and support.
IDENTIFICATION
APPRAISAL Producing appraisal reports that summarise
the available evidence on a health technology,
including input from experts.
Providing authoritative, evidence-based Guidance
to inform decision makers on whether they
should adopt a technology.
Building learning and skills in health technology
assessment, including the appraisal of clinical,
safety and economic evidence.
APPRAISAL
ADOPTION Monitoring the uptake of guidance across Wales.
This includes both our HTW Guidance and
guidance from the National Institute for Health
and Care Excellence.
Making recommendations on research priorities
to improve the available evidence.
Encouraging uptake of effective technologies,
and disinvestment in technologies that are no
longer effective.
ADOPTION
Discover more
Web www.healthtechnology.wales
Telephone +44 (0)29 2046 8947
Twitter twitter.com/HealthTechWales
LinkedIn www.linkedin.com/company/healthtechnologywales/NICE strategy 2021 to 2026 Dynamic, Collaborative, Excellent Our transformation starts now. We’ve launched an ambitious new strategy, which explains how we’re working more collaboratively than ever before. We’re sharing our knowledge and expertise internationally and learning from other health systems, to inform our work. To find out more: visit our virtual exhibition booth at the HTAi 2021 Virtual Annual Meeting or go to www.nice.org.uk/strategy
NICE International
Working with you to improve global health outcomes
We are NICE International – part of the UK’s
National Institute for Health and Care Excellence
and closely connected to the National Health Service.
“NICE was an affirming
influence and an inspiring
We aim to help countries improve their nation’s
force to improve our
health and wellbeing by sharing our knowledge and
experience of guideline development and health policies and practices
technology assessment. in transparency and
accountability, including
We collaborate the world over to enable
health organisations, ministries and government how to have useful
agencies to: consultations with
experts and patients,
make better and more cost-effective
health and care decisions liaise with pharmaceutical
allocate finite resources companies and network
improve care quality with academia.”
reduce variation in access to care.
Dr Marita Reyes
We’ll work with you to understand your questions,
Chair of the HTA Council
challenges or ambitions and tailor our support of the Philippines
services to meet your needs.
To find out more visit
www.nice.org.uk/niceinternational © NICE 2021. All rights reserved. Subject to www.nice.org.uk/terms-and-conditionsNovartis-sponsored
symposium
Novartis sponsored symposium at the Health Technology
Assessment international Congress (HTAi 2021)
Converging novel HTA and access
pathways in adaptable healthcare systems
Tuesday 22 June 2021, 16:00–17:00 (CEST)
HTAi Annual Meeting Manchester UK, Virtual Meeting
Novartis is committed to reimagine medicine to transform healthcare systems (HCS) and improve
access to patient-populations in need. However, bringing newer technologies and 21st century
medicines to patients can challenge traditional funding thresholds and approaches.
The existing health technology assessment (HTA) frameworks can be limited in evaluating the
complexity of advances in HCS. The use of adaptive frameworks and disruptive launch models
may have the ability to address these needs. One of the key elements of adaptive HTAs should
therefore be the development of multi-stakeholder collaborative networks for innovations to
flourish and spread, thus accelerating countries’ progress on health-related priorities.
In our endeavor to bridge the gap between HCS/HTA and patient access, we have arranged a
symposium on “Converging novel HTA and access pathways in adaptable healthcare systems” at
the HTAi Annual Meeting Virtual Event 2021. We aim to understand through the eyes of the HTA/
payers, industry, and policy-makers, the key attributes and challenges between innovation and
recent HTA frameworks to accelerate access.
This satellite symposium is organized and funded by Novartis Pharma AG
© Novartis Pharma AG, 2021, CH-4002 Basel, Switzerland
May 2021Novartis sponsored symposium at the Health Technology
Assessment international Congress (HTAi 2021)
Converging novel HTA and access
pathways in adaptable healthcare
systems
Tuesday 22 June 2021, 16:00–17:00 (CEST)
HTAi Annual Meeting Manchester UK, Virtual Meeting
Chair: Michele Mestrinaro, Switzerland
16:00 Welcome and introduction
Michele Mestrinaro
Global Head of Pricing and Access Policy, Novartis AG, Switzerland
Participant introductions and opening remarks
Prof. Zoltán Kaló
Professor of Health Economics at Center for HTA, Semmelweis University
Budapest, Hungary
Dr. Karen Facey
Evidence Based Health Policy Consultant, Scotland
Prof. Jinxi Ding
Professor and Vice Dean, School of International Pharmaceutical Business,
China Pharmaceutical University, China
Dr. Laurie Lambert
Real World Evidence Lead at Canadian Agency for Drugs and Technologies
in Health, Canada
16:10 Q&A – Moderated panel discussion
All Faculty
16:45 Q&A - Audience
All Faculty
16:55 Closing Remarks
Michele Mestrinaro
For any questions related to the symposium, please contact:
Dr. Judit Bánházi, Global HEOR Director, Novartis Pharma AG, Basel, Switzerland
judit.banhazi@novartis.com | +41799375703
The symposium recording will also be available for on-demand viewing on the HTA Congress website, until September 2021.
This satellite symposium is organized and funded by Novartis Pharma AG
© Novartis Pharma AG, 2021, CH-4002 Basel, Switzerland
May 2021ASERNIPS
We are global leaders in health technology
assessment. Our team of experts assess
technologies relevant to surgeons and the
surgical environment; and, we are uniquely
positioned within a Medical College providing us
access to clinicians. We will work closely with you
to identify your specific requirements and provide
individualized and highly insightful safety and
effectiveness assessments, statistical analyses
and health economic reviews.
Our services include:
Surgical procedure assessments that review
existing or emerging surgical practices to inform
funding decisions.
Medical device assessments of new and
emerging devices to inform investment and
approval decisions.
Pathology test and diagnostic imaging reviews
that assess validity and clinical utility and impact
on patient management.
Training services including the development and
delivery of Health Technology Assessment training
materials and research into Simulation-based
education for surgery.
To discuss your technology assessment
needs please contact Dr David Tivey
at +61 410 451 663 or
racs.asernip@surgeons.org.
We look forward to meeting you during HTAi 2021.Exploring the impact of patient voice
and its representation in the HTA
organization decision-making process
There has been concerted effort in recent years to further integrate the patient voice in HTA. The perspective
of the patient and their caregiver may differ from the HCP, and tends to elevate safety and tolerability of
treatment.1,2 These efforts are initiating or already underway around the globe, led by HTA, regulatory
agencies, and advocacy groups.3
HTA organizations incorporating patient input in their assessments4:
SMC (Scotland)
IQWIG
NICE (Germany)
(UK)
HAS
(France)
The European Patients Academy
on Therapeutic Innovation (EUPATI)
recommends that HTA organisations PBAC
develop frameworks to systematically (Australia)
incorporate patient input to HTAs.5
These countries are incorporating patient preference through the use of
discrete choice experiment (DCE) methodology in their HTA decision-making3:
Germany’s IQWIG recommends England’s NICE has used it Sweden recommends use when
its use to estimate the aggregate in the unmet need section of the QALY is inappropriate, such
benefit in economic evaluations3,4 NICE dossiers and selection as when evaluating changes in
of trial endpoints3,6 short-term pain3
HCP=healthcare provider; HAS=Haute Autorité de Santé; NICE=National Institute for Health and Care Excellence; SMC=Scottish
Medicines Consortium; IQWIG=Institute for Quality and Efficiency in Healthcare; PBAC=Pharmaceutical Benefits Advisory Committee;
QALY=quality-adjusted life-year.What is DCE?7
Discrete choice experiment (DCE) quantifies preference values toward various treatment attributes, allowing
for estimation of the relative importance of different aspects of care or outcomes. Consideration of these
stated priorities during HTA would help ensure access to products which deliver best value by addressing
stated priorities.
Case Study: DCE in nmCRPC
For non-metastatic castration-resistant prostate cancer (nmCRPC), DCE can be used to capture treatment
preferences and offer insights into patient and stakeholder needs.
Qualitative phase identifying treatment needs and important attributes1
Fatigue, skin rash, cognitive problems, serious falls, serious fractures, overall survival, time to pain progression
Quantitative phase capturing choice between hypothetical treatment options differing in
attribute performance1,2
(patients: N=143; caregivers: N=149; physicians: N=149)
14 treatment choice questions, each comparing 2 hypothetical medication profiles varying on the 7 attributes1,2
Number of months of overall survival that patients, caregivers, and physicians
were willing to trade in return for an improvement in adverse events1,2
Patient Caregiver Physician
(N=143) (N=149) (N=149)
Cognitive problems
(moderate to none) >9 months >9 months 2.5 months
Fatigue
(moderate to none) >9 months 8.4 months 0.8 months
Serious fractures
(5% to none) >9 months >9 months 5.3 months
Key Takeaways
• Since patients with nmCRPC are generally asymptomatic, AEs from treatment are of even greater
importance when patients are considering treatment options
• These study results indicate that nmCRPC patients and caregivers preferred treatments with lower AE
burden and were willing to forego substantial duration of OS to reduce the risk and severity of AEs1
• Among the AEs evaluated, patients most valued the reduction of serious fracture, serious fall, and
cognitive problems1
• Patient preferences can differ from those of physicians, allowing the patient to provide real-world
understanding of their treatment, which can help improve shared decision-making
See more on the Bayer Exhibitor page
AE=adverse event; OS=overall survival.
References: 1. Srinivas S, Mohamed AF, Appukkuttan S, et al. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer
treatment. Cancer Med. 2020;9(18):6586-6596. 2. Srinivas S, Mohamed AF, Appukkuttan S, et al. Physician preferences for non-metastatic castration-resistant prostate
cancer treatment. BMC Urol. 2020;20(1):73. doi:10.1186/s12894-020-00631-4 3. Marsh K. Patient preferences in health technology assessment in Europe: recent advances
and future potential. The Evidence Forum. Fall 2019. https://www.evidera.com/patient-preferences-in-health-technology-assessment-in-europe-recent-advances-and-
future-potential/. Accessed May 17, 2021. 4. Chachoua L, Dabbous M, François C, Dussart C, Abelléa S, Toumi M. Use of patient preference information in benefit-risk
assessment, health technology assessment, and pricing and reimbursement decisions: a systematic literature review of attempts and initiatives. Front Med. 2020;7:543046.
doi: 10.3389/fmed.2020.543046 5. Hunter A, Facey K, Thomas V, et al. EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health
Technology Assessment. Front Med. 2018;5:231. doi: 10.3389/fmed.2018.00231 6. National Institute for Health and Care Excellence. Baricitinib for moderate to severe
rheumatoid arthritis. http://www.nice.org.uk/guidance/ta466. Published August 9, 2017. Accessed May 17, 2021. 7. Trapero-Bertran M, Rodriguez-Martin B, Lopez-Bastida
J. What attributes should be included in a discrete choice experiment related to heath technologies? A systematic literature review. PLoS One. 2019;14(7):e0219905. doi:
10.1371/journal.pone.0219905
© 2021 Bayer. All rights reserved. BAYER and the Bayer Cross are registered trademarks of Bayer. MAC-PF-ONC-ALL-0038-1 06/21Online MSc Health Technology Assessment
Want to be a 21st century HTA practitioner? Students may then select from a range of optional
Governments around the world are using Health courses:
Technology Assessment (HTA) to inform
decision-making. Get involved and enhance • Outcome measurement and valuation for HTA
your career by acquiring quantitative and qualitative • Qualitative research methods for HTA
research skills in support of HTA. Join our online • HTA in a global context
distance learning programme, 2.5-6 years part-time • Survival analysis for HTA
(MSc), 2-4 years part-time (PgDip), 1-2 years • Foundations of decision analytic modelling
part-time (PgCert). The online delivery includes • Data science
video presentations by teaching faculty, live • Maximising the value of clinical trial data
lectures over the internet, weekly exercises,
directed readings and student/faculty interaction on
discussion forums. Students can study to Certificate, Diploma or Masters
Our MSc comprises the following core courses: (includes a research project) level.
For more details please visit
• HTA: policy and principles www.gla.ac.uk/hta
• Statistical methods for HTA and
evidence-based medicine
• Health economics for HTA Continuous Professional Development (CPD)
• Research project Our CPD programme includes our new live, online
(core ‘course’ only for MSc level) course Maximising the Value of Clinical Trial Data. In
addition, the online MSc HTA courses listed above
can be taken as non-accredited CPD. They run at the
same time as the MSc courses so please visit
www.gla.ac.uk/hta for more details of dates.Research
Our research is divided into eight programmatic Analysis of Linked Health Data
themes: This programme encompasses all research
work in HEHTA that is associated with statistical,
Global HTA
epidemiological and economic analysis of linked
This programme considers HTA and decision-making
health data sets.
in different contexts, exploring variation, within and
between, high-income and low- and middle-income Incorporating Perspectives and Experiences
countries. This programme focuses on the application of
qualitative methods of data collection and analysis,
Economics of Population Health
and evaluation of interventions to improve health.
This programme is concerned with the development
of methods and related empirical work associated Evidence Synthesis
with the economic evaluation of ‘up-stream’ This programme encompasses all research work
population health interventions. associated with systematic review, and meta-analysis
of direct, indirect and network evidence.
Decision Analytic Modelling
The programme encompasses research work
associated with conducting an evaluation using
modelling or simulation methods. It cuts across
and interacts with many of the other programmatic
themes of HEHTA.
Postgraduate Research opportunities are available,
Economic Evaluation alongside Clinical Trials
with many of our staff supervising doctoral and
This programme encompasses all research work
postgraduate research students in various subject
associated with conducting an economic appraisal
areas relating to health economics and HTA. Our
as part of a clinical trial.
students’ work results in high quality publications,
Economics of Precision Medicine international conference presentations and
This programme focuses on evaluation of stratified contributes to HEHTA’s international reputation
medicine and early stage technologies. across our eight research themes.
Contact us:
Health Economics and Health Technology Assessment (HEHTA)
1 Lilybank Gardens, Glasgow G12 8RZ
0141 330 4010
www.gla.ac.uk/hehta
Twitter: @HEHTAGlasgow © University of Glasgow 2021
Design: MVLS Design and Communication, University of Glasgow
The University of Glasgow, charity number SC004401Innovating for minimally invasive care
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, Intuitive brings more than two decades of leadership
California, is a global technology leader in minimally in robotic-assisted surgical technology and solutions
invasive care and a pioneer of robotic-assisted surgery. to its offerings and develops, manufactures, and
As part of our mission, we believe that minimally markets the da Vinci surgical system and the Ion
invasive care is life-enhancing care. Through ingenuity endoluminal system.
and intelligent technology, we expand the potential
of physicians to heal without constraints. Learn more at Intuitive.com.
8.5 million+
Number of minimally invasive procedures
24 thousand+
Total number of peer reviewed
performed worldwide through 2020 using scientific articles that reference
the da Vinci surgical system. da Vinci surgical systems*.
1.2 million+
Number of procedures performed in
25.4 seconds
How often a surgeon begins a procedure
2020 using the da Vinci surgical system. using the da Vinci surgical system.
67
countries
5,989
da Vinci systems
around the world
As of December 15, 2020.
*
© 2021 Intuitive Surgical, Inc. All rights reserved. Product and brand names/logos are trademarks or
registered trademarks of Intuitive Surgical or their respective owner. See www.intuitive.com/trademarkscambridge.org/thc
Official Journal of
27/01/20 12:35 PMInternational Journal of
Technology
Assessment
in Health Care
serves as a forum for the wide range of
health policy makers and professionals
interested in the economic, social, ethical,
medical and public health implications of
health technology.
Looking for articles on
Innovation Through HTA?
We have over 1,200 articles on innovation.
Browse our articles at cambridge.org/THC.
Official Journal ofExecutive MSc
Evaluation of Health
Care Interventions
and Outcomes
In collaboration with the National Institute
for Health and Care Excellence (NICE)
Study alongside full-time work
The combination The Executive MSc in Evaluation of Health Care Interventions
and Outcomes delivers training in health services research,
of LSE’s world- health economics, health outcomes research and health policy.
75% LSE
25% NICE
leading teaching and The two-year programme has been developed in collaboration
research excellence and with NICE, known internationally for the scientific rigour of Teaching
its approach to evaluating the effectiveness and value of
NICE’s standing as a
medicines, medical technologies, treatments and interventions.
national authority and
global leader in health For working health professionals
The programme is designed for professionals from a wide
technology assessment
range of backgrounds in the health sector who are looking
and guidance offers an to progress in their career and develop as health policy
2 years
unparalleled degree of leaders by building on their skills in health economics, health
outcomes research, and management.
rigour and professional
relevance. Teaching timetable
Over two years, the courses will be delivered in four 8 courses
Professor Elias Mossialos intensive two-week teaching blocks at the London School
Deputy Head of Department and of Economics and Political Science. This schedule allows
Director of LSE Health participants to complete the degree alongside full-time work.
Visit our website to apply 4 teaching
blocks at LSECourses
Year 1
Introduction to Evaluation in Health Care
Gain an in-depth overview of the key principles and models used to evaluate health
care interventions, programmes and policies.
Systematic Review and Meta-analysis
Learn the key principles of evidence review and synthesis needed to interpret
existing evidence to evaluate health care interventions.
Economic Evaluation in Health Care
Develop your strategic decision-making skills by learning how to understand,
critically appraise, develop, and interpret cost-effectiveness analyses to make
specific recommendations and define best practice.
Dissertation in Evaluation of Health Care Interventions and Outcomes
Explore a topic of your choice in the field of health services research and health
policy, and integrate the methodology and knowledge learned across your courses
to address a key issue.
Year 2
Quasi-experimental Evaluation of Health Care Programmes
and Policies
Gain the skills needed to design, critically appraise, and conduct quasi-
experimental studies evaluating health policies, programmes, and interventions.
Randomised Evaluation of Health Programmes and Policies NICE has 20
Learn to design and conduct a randomised evaluation through hands-on and years’ experience
intuitive training while exploring the rationale of best-practice experimental design.
in evidence-based health
Statistical Methods in Health Care Economic Evaluation care decision making
Develop the statistical and modelling techniques necessary to apply economic
evaluation to the health care sector by mastering a range of statistical methods.
and we are delighted to
be able to partner with
Principles of Health Technology Assessment
LSE in order to share
This course is aimed at introducing the key principles of health technology
assessment, its operational modalities, the different models of value assessment this expertise amongst
and how they link to decision-making. professionals who are
looking to enhance their
Please note that course regulations may change. For the most up-to-date list of courses, skills in this area.
please visit: lse.ac.uk/NICE-exec-MSc
Jeanette Kusel
Apply now to secure your place Director for NICE Scientific AdviceYou can also read
